Stock Ratings / Health Care / BTMD / dividends

FTLF (45) ISPR (24) MTEX (45) MDWD (51) ⌘ Pro Terminal →

Biote Corp. (Class A) (BTMD) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.17 +1.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.17

Biote Corp. (Class A) (BTMD) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $42.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BTMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BTMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Biote Corp. (Class A) (NASDAQ: BTMD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $1.17 (+1.74% 1D, market cap $42.0M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BTMD ranks #301 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BTMD compare to FTLF and ISPR in the Health Care sector?

▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), BTMD carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 85.0%. By comparison, FTLF (FitLife Brands Inc.) holds a D grade (45/100 RQD, P/E 11.7x, ROIC 5.4%, cap $74.3M) and ISPR (Ispire Technology Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $79.1M). Among the 5-stock peer group, FTLF leads on earnings multiple (11.7x) while BTMD leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BTMD?

▼

Per BTMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819253), Biote Corp. (Class A) generated $192.2M in revenue (-2.5% YoY), $27.0M in net income, and $30.2M in free cash flow against $107.6M in total assets and $95.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.17 (+0.12%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 15.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-3.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BTMD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (50/100 Composite)

🔍 WHY BTMD SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+14/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 15.7% FCF Margin ($30.2M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (24% of score)

Altman Z-Score 2.50 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.14-5.3% Next Q

Q2 (-2Q)

Grade D$1.08+6.5% Next Q

Q3 (-1Q)

Grade D$1.15+1.7% Next Q

Current

Grade D$1.17-1.4% Hist 90D α

Trajectory: D (42) → D (50)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BTMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BTMD currently carries a cautious 50/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.29) and Max Pain ($1.23) forces dealer call-delta covering toward $3.13.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.24% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BTMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BTMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 50%NO 50%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

5.91% Total Yield

4.11% Cash ($0.05/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

41/100 • ELEVATED PAYOUT WATCH

FREE CASH FLOW PAYOUT RATIO

95.4% of FCF

8 consecutive years of payout growth

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (9.4% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $24,557

Est. Year-10 Shareholder Yield: $1,451/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.9K

Yr 1

$12.0K

Yr 2

$13.1K

Yr 3

$14.3K

Yr 4

$15.7K

Yr 5

$17.1K

Yr 6

$18.8K

Yr 7

$20.5K

Yr 8

$22.4K

Yr 9

$24.6K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BTMD)

✓Walkthrough of BTMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BTMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.55%⚡ TESTING RESISTANCE

2026-11-02O $1.15H $1.17L $1.15C $1.17VOL 127.0K

RES: $1.21SUP: $0.89SMA50: $1.29SMA200: $1.82

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BTMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BTMD Butterfly Map → + Track BTMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-15.0%/yr Implied 5Y Growth

vs. -2.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BTMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BTMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BTMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BTMD)

Health Care Rank #301 of 1016 ⚔️ FTLF vs BTMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BTMD vs. FTLF, ISPR, MTEX, MDWD)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Biote Corp. (Class A) (BTMD) ranks #301 by composite RQD confidence (50/100, grade D) and #768 by equity capitalization ($42.0M). Within this direct 5-issuer industry benchmark cohort, FTLF leads on earnings valuation at 11.7x trailing P/E, while BTMD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. MDWD currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with BTMD at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BTMD ACTIVE Biote Corp. (Class A)	D	50/100	—	—	85.0%	+1.74%	$42.0M	Benchmark Subject
FTLF FitLife Brands Inc.	D	45/100	11.7x	43.1%	5.4%	-4.70%	$74.3M	/ftlf-vs-btmd →
ISPR Ispire Technology Inc.	E	24/100	—	17.8%	-35.0%	-1.44%	$79.1M	/ispr-vs-btmd →
MTEX Mannatech Incorporated	D	45/100	—	74.9%	-35.0%	-2.23%	$16.1M	/mtex-vs-btmd →
MDWD MediWound Ltd.	D	51/100	—	—	—	+2.21%	$178.9M	/mdwd-vs-btmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001819253

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Biote Corp. (Class A) (BTMD) reported GAAP revenue of $192.2M (-2.5% vs. FY2024 revenue of $197.2M , and +3.7% cumulative change since FY2023) , GAAP net income of $27.0M, operating cash flow of $35.2M, and free cash flow of $30.2M (-22.2% YoY). On the balance sheet, BTMD closed FY2025 with $107.6M in total assets against $95.8M in total debt (Altman Z-Score: 2.50, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$192.2M	$27.0M	$35.2M	$30.2M	$107.6M	$95.8M
FY2024 (FY)	2024-12-31	$197.2M	$3.2M	$45.2M	$38.8M	$122.4M	$101.2M
FY2023 (FY)	2023-12-31	$185.4M	$3.3M	$26.9M	$26.9M	—	—

3. BTMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BTMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BTMD compare to FTLF and ISPR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BTMD?

Where is BTMD trading relative to its 50-day, 200-day, and 52-week technical levels?

BTMD last traded at $1.17 (+1.74% on volume of 127,002 shares), positioning the stock -9.30% below its 50-day simple moving average ($1.29) and -35.71% below its 200-day simple moving average ($1.82). Across its 52-week range of $1.00 to $2.98, BTMD sits at the 8.6% percentile with a 14-day RSI of 49.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.02 to $1.32).

BTMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does BTMD pay a dividend and is it safe?

Biote Corp. (Class A) (BTMD) offers a 4.11% cash dividend yield ($0.05 annualized) and 5.91% total shareholder yield including buybacks. Roarable rates its payout coverage as ELEVATED PAYOUT WATCH.

Direct Sub-Reports: BTMD RQD Cockpit BTMD 12M Forecast BTMD Earnings & Move BTMD Dividends & DRIP BTMD Insiders & 13F BTMD Whale Options BTMD Profit Sankey BTMD News & Why